-+ 0.00%
-+ 0.00%
-+ 0.00%

MBX Biosciences FY 2025 net loss rose 40% to USD 86.97 million, while G&A expenses jumped 75% to USD 18.9 million

Reuters·03/12/2026 12:05:06

Please log in to view news